The rationale for combining anti-PD-1 therapy with a hypomethylating agent originates from data showing upregulation of PD-L1 and PD-L2 mRNA in CD34-positive cells from patients with AML following treatment with a hypomethylating agent and is discussed in further detail below (94). This evidence concerns the gene CD274 and acute myeloid leukemia.